Clinical Trials
224
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (164 trials with phase data)• Click on a phase to view related trials
Analysis of the Gut Microbiota Composition After Consumption of Probiotic Bacteria
- Conditions
- Microbiota Analysis in Healthy Subjects
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Lund University
- Target Recruit Count
- 60
- Registration Number
- NCT07046897
- Locations
- 🇸🇪
Department of Process and Life Science Engineering, Lund University, Lund, Sweden
Evaluation Viral RNA and Virus Infectivity in Exhaled Air Before and After Use of One Dose With ColdZyme Mouth Spray
- Conditions
- URTI - Viral Upper Respiratory Tract Infection
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Lund University
- Target Recruit Count
- 200
- Registration Number
- NCT07041671
- Locations
- 🇸🇪
Lund University, Lund, Sweden
Exercise Training Among Children With Cerebral Palsy to Increase Health and Well-being - A Feasibility Study
- Conditions
- Children With Cerebral Palsy Who Are AmbulantCerebral Palsy GMFCS-ER I-II
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Lund University
- Target Recruit Count
- 20
- Registration Number
- NCT07025694
- Locations
- 🇸🇪
Medical Faculty, Lund University, Lund, Scania, Sweden
Effectiveness of Perineorrhaphy in Pelvic Organ Prolapse Surgery
- Conditions
- Pelvic Organ Prolapse Vaginal SurgeryPelvic Organ Prolapse (POP)
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Lund University
- Target Recruit Count
- 40646
- Registration Number
- NCT07006129
- Locations
- 🇸🇪
Lund University, Malmö, Sweden
A Municipality Implemented Behavioural Intervention to Improve Quality of Life Among Older Adults
- Conditions
- Quality of Life
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Lund University
- Target Recruit Count
- 40
- Registration Number
- NCT06807060
- Locations
- 🇸🇪
Gothenburg Municipality, Gothenburg, Sweden
🇸🇪Jönköping Municipality, Jönköping, Sweden
🇸🇪Lund Municipality, Lund, Sweden
- Prev
- 1
- 2
- 3
- 4
- 5
- 45
- Next
News
Varenicline-Bupropion Combination Shows Promise for Alcohol Use Disorder Treatment
A 13-week randomized trial of 384 patients with moderate to severe alcohol use disorder found that combining varenicline and bupropion produced approximately twice the effect of currently available medications.
NextCell Pharma Completes Patient Dosing in Phase II ProTrans-Young Trial for Pediatric Type 1 Diabetes
NextCell Pharma has successfully completed treatment of all patients in the ProTrans-Young Phase II clinical trial, marking the completion of patient dosing in the company's largest clinical study to date.
Scientific Breakthrough Reveals How Alpha1H Targets Bladder Cancer Cells
Hamlet BioPharma and Lund University researchers have discovered that Alpha1H, a bladder cancer drug candidate, targets the endoplasmic reticulum in tumor cells, causing it to collapse like a net around toxic components.
Concussions in Hockey Players Linked to Doubled Risk of Depression and Tripled Risk of Burnout
Hockey players who suffered three or more concussions had twice the risk of depression symptoms compared to those without concussion history, according to new Swedish research.
Early Combination of Statins and Ezetimibe Could Prevent Thousands of Heart Attacks, Study Finds
Researchers from Imperial College London and Lund University found that early combination therapy with statins and ezetimibe significantly reduces the risk of subsequent heart attacks and death in cardiac patients.
Cantargia Initiates First Clinical Trial of Nadunolimab for AML and MDS Treatment
Swedish biotech Cantargia has enrolled the first patient in a Phase Ib/IIa trial investigating nadunolimab in combination with standard chemotherapy for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).